Cost-benefit of outcome adjudication in nine randomised stroke trials

Peter J Godolphin¹,², Philip M Bath³, Ale Algra⁴,⁵, Eivind Berge⁶, John Chalmers⁷, Misha Eliasziw⁸, Graeme J Hankey⁹, Naohisa Hosomi¹⁰, Annamarei Ranta¹¹, Christian Weimar¹², Lisa J Woodhouse³, Alan A Montgomery¹

Corresponding Author: Peter J Godolphin

Corresponding Author’s Email: p.godolphin@ucl.ac.uk

Corresponding Author’s Phone Number: +44 (0)20 7670 4801

Corresponding Author’s Address: MRC Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, 90 High Holborn, London, WC1V 6LJ

Institutions:

1: Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK

2: MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK

3: Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK

4: Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

5: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

6: Department of Internal Medicine, Oslo University Hospital, Oslo, Norway

7: The George Institute for Global Health, University of NSW, Sydney, Australia

8: Department of Public Health and Community Medicine, Tufts University, Boston, USA

9: Medical School, The University of Western Australia, Perth, Australia

10: Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
Total number of tables and figures: Tables 3

Running head: Cost of adjudication in stroke trials

Word count: 1906/2000

Grant support: Peter J Godolphin was funded for this summary of independent research by the National Institute for Health Research (NIHR)’s Doctoral Research Fellowship Programme (DRF-2016-09-57) and also supported by the UK Medical Research Council (MC_UU_12023/24).
Abstract:

**Background:** Central adjudication of outcomes is common for randomised trials and should control for differential misclassification. However, few studies have estimated the cost of the adjudication process.

**Methods:** We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials (25,436 participants). The costs included adjudicators’ time, direct payments to adjudicators, and coordinating centre costs (e.g. uploading cranial scans and general set-up costs). The number of events corrected after adjudication was our measure of benefit. We calculated cost per corrected event for each trial and in total.

**Results:** The primary outcome in all nine trials was either stroke or a composite that included stroke. In total, the adjudication process associated with this primary outcome cost in excess of £100,000 for a third of the trials (3/9). Mean cost per event corrected by adjudication was £2295.10 (standard deviation: £1482.42).

**Conclusions:** Central adjudication is a time-consuming and potentially costly process. These costs need to be considered when designing a trial and should be evaluated alongside the potential benefits adjudication brings to determine whether they outweigh this expense.

**Keywords:** Adjudication, stroke, clinical trial
Introduction:

In randomised stroke trials, central adjudication of outcomes is common[1]. Adjudicators are typically blinded independent experts who review individual participant data and provide an assessment of outcome(s). Clinicians at local sites often assess the same outcomes but these data are commonly discarded. Central adjudication should reduce both random and systematic bias, but studies have shown that it has limited impact on the estimated treatment effect in randomised trials[1-3]. Thus, it is important to estimate the cost of the adjudication process, in order to establish whether the cost outweighs the perceived benefit of the process.

The cost of adjudication could be estimated as the direct cost paid to the adjudicator, which is often a menial amount (£10-15 per adjudication). However, this does not take into account the time it takes the adjudicator to undertake their assessment of the individual participant data. Furthermore, preparing data for the adjudicators, blinding and obtaining source information and general set-up costs are other expenses associated with the adjudication process that are borne by the co-ordinating centre (often a clinical trials unit). Thus, the cost of the adjudication process can be made up from (1) direct costs paid to the adjudicators; (2) time costs of the adjudicators; and (3) co-ordinating centre costs.

The aim of this study was to estimate the cost of central adjudication in randomised stroke trials and present this cost in terms of the number of events corrected by the central adjudication process.

Methods:

Data Collection

Authors of stroke trials included in a systematic review[1] were invited to provide data on the cost of outcome adjudication in an online questionnaire (see Supplemental Material, Cost of Adjudication Questionnaire). Data collected included time required to adjudicate events, adjudicators’ approximate salary in today’s costs and how disagreements were handled.

Benefit of Adjudication
Our measure of benefit of the adjudication process was the number of events corrected after adjudication. This outcome provides an estimate of the agreement between the adjudicators and site investigators and quantifies the extent to which the adjudication process changes the trial outcome. However, this measure does not take into account whether the adjudication process impacts on the treatment effect estimate. We collected the number of events corrected after adjudication in our previous systematic review[1].

**Cost of Adjudication**

All costs were taken from a societal perspective and were reported in various currencies (Australian dollars, Euros, Pounds Sterling and New Zealand Dollars). If costs were not entered as pounds sterling, then all other currencies were converted into pounds sterling on 16th May 2019.

We calculated adjudicator hourly salary assuming that adjudicators worked 1680 hours a year (40 hours a week for 42 weeks of the year). Total time was determined using the amount of time it took for each adjudication, the number of events adjudicated and whether events were adjudicated multiple times. In addition to staff salary costs assumed to be borne by employers rather than study funders, we also assumed that adjudicators were directly paid £10 per event from study funds. This is not paid in all studies; however, it enables a comparison between studies and where paid, is typical of the amount in UK studies. Costs of resolving disagreements was based on staff time only.

For each study, we assumed a fixed set-up cost to create a website for data sharing (brain scans, video footage etc.) and for adjudicators to submit their final assessments. We estimated this to require 40 hours of a database programmer (cost £650). We also assumed that each adjudicated event required four hours of administrative time at the co-ordinating centre (cost £40 per adjudicated event).

**Statistical Analysis**

Continuous variables were summarised with mean and standard deviation, or median and interquartile range. Categorical variables were described with frequency counts and percentages. The cost per event corrected was determined for each trial and for all trials.

**Results:**
Authors from nine trials, comprising 25,436 participants, completed the questionnaire and these nine trials are included in this study (4-12) (Table 1). All outcomes adjudicated were either stroke or a composite including stroke, with two trials including transient ischaemic attack as part of their outcome of stroke (See Supplementary Material, Supplementary Table I). In the majority of the trials (7/9, 77%) adjudicators reviewed only those events identified by the site investigators, but for two of the studies adjudicators assessed a larger number of events, by adjudicating either suspected events or all participants (See Supplementary Material, Supplementary Table I). The time taken per adjudication range from five minutes to two hours. However, the trial with the lowest time had three adjudicators assess each event (Table 2). All other trials assessed each event either once or twice. The trial with highest adjudicator salary cost was around twice that of the lowest.

Three of the trials (33%) had no disagreements (see Supplementary Material, Supplementary Table II). For trials that had disagreements between adjudicators, the cost and time associated with this was far less than that associated with the original adjudication (Table 3). Two studies had no events corrected after adjudication, although the total cost of the adjudication process for both of these was less than £4,000. Three trials had a total estimated cost of the adjudication process in excess of £100,000. On average, across the seven trials with corrected events, adjudication cost £2,295.10 per event corrected (standard deviation: £1482.42).

Discussion:

In this analysis of nine randomised trials we found that, on average, adjudication costs approximately £2,300 per corrected event, with the total cost of adjudication exceeding £100,000 for three trials. Our study assumed a fixed cost of £40 per adjudication for the co-ordinating centre, as it was not possible to collect accurate data retrospectively on a trial-by-trial basis. Another study estimated the co-ordinating centre cost for the adjudication process in a thromboprophylaxis trial, to be approximately £55 per adjudicated event (13) compared to our assumption of £40. Thus, we may have marginally underestimated the total cost of the adjudication process.

The nine trials included in this study all had binary primary outcomes, and when these were composites, they were constructed from binary components. There may be different types of outcomes that have greater or worse cost-benefit of adjudication than the outcomes described in this study. For example, outcomes with greater objectivity, such as disabling stroke, may have less need
for adjudication when compared to more subjective outcomes, such as functional status measured on
the modified Rankin Scale or causality of adverse events\textsuperscript{[14]}. In addition, the method of adjudication
could have large cost-benefit implications. For studies where adjudicators only assess site-reported
events, the cost will be lower than studies in which all participants are adjudicated. However, when
adjudicators only assess site-reported events, the adjudicators cannot identify additional events that
could have been missed by the site investigators, potentially limiting the benefit of adjudication.
Furthermore, the blinding status of the site investigators has the potential to influence the benefit that
can be gained from adjudication\textsuperscript{[15]}, and this information should be used when designing a clinical trial
to understand the potential costs and benefits adjudication can bring.

This study has a number of limitations. Firstly, the nine trials included span a 30-year time interval and
cover a range of academic and industry funded trials, as well as including funding agencies that have
varied sources of financial support (e.g. charities, government agencies). Therefore, the variability in
these factors may have contributed to the disparity seen between the time taken for adjudication,
which may have influenced the estimated cost of adjudication in this study. Secondly, this study relies
on retrospectively collected cost data. Some of the trials included in this study performed their
adjudications decades ago, so it is possible that this data is not as accurate as data collected
prospectively. However, this is the first study that we are aware of that has attempted to estimate the
entire cost of the adjudication process.

As eluded to above, further research is warranted that prospectively collects the costs of central
adjudication in an ongoing trial. A previous study showed that adjudications can take months to
complete\textsuperscript{[14]}, and a prospective study could accurately measure the time taken for the multitude of
processes that are involved in implementing adjudication in a clinical trial. Furthermore, combining
cost data with the approach of Kahan and colleagues\textsuperscript{[16]} could give further understanding to the cost-
benefit of increasing the number of adjudicators or varying the method of adjudication.

To conclude, central adjudication has been shown to control for differential misclassification and is
important for trials where blinding is inadequate or impossible\textsuperscript{[15]}. However, it can be costly, and these
costs need to be estimated when designing a trial to evaluate whether the benefits of central
adjudication outweigh the potential expense.

Acknowledgements:
The authors would like to thank two anonymous reviewers for their useful comments and suggestions on an earlier version of this manuscript.

**Author contributions:**

PJG, AAM and PMB conceived the study and applied for funding; PMB, AA, EB, JC, ME, GJH, NH, AR, CW, LJW provided the data for the study; PJG analysed the data; All authors interpreted the data; PJG wrote the first draft of the manuscript; all authors commented critically on the manuscript for important intellectual content and read and approved the final manuscript.

**Funding:**

PJG was funded for this summary of independent research by the National Institute for Health Research (NIHR)'s Doctoral Research Fellowship Programme (DRF-2016-09-57) and also supported by the UK Medical Research Council (MC_UU_12023/24). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. PMB is Stroke Association Professor of Stroke Medicine and is a NIHR Senior Investigator.

**References:**

1. Godolphin, P.J., et al., *Outcome assessment by central adjudicators versus site investigators in randomised stroke trials: A systematic review and meta-analysis*. Stroke, 2019.

2. Pogue, J., S.D. Walter, and S. Yusuf, *Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs*. Clin Trials, 2009. 6(3): p. 239-51.

3. Ndounga Diakou, L.A., et al., *Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates*. Cochrane Database Syst Rev, 2016. 3: p. Mr000043.

4. Weimar, C., et al., *Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting: A Randomized Clinical Trial*. Stroke, 2017. 48(10): p. 2769-2775.

5. ESPRIT Study Group, *Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial*. Lancet, 2006. 367(9523): p. 1665-73.

6. Ranta, A., et al., *Cluster randomized controlled trial of TIA electronic decision support in primary care*. Neurology, 2015. 84(15): p. 1545.

7. Berge, E., et al., *Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study*. HAEST Study Group. *Heparin in Acute Embolic Stroke Trial*. Lancet, 2000. 355(9211): p. 1205-10.
8. Hosomi, N., et al., The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine, 2015. 2(9): p. 1071-8.

9. Barnett, H.J.M., et al., Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med, 1991. 325(7): p. 445-53.

10. PROGRESS Collaborative Group, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001. 358(9287): p. 1033-41.

11. Bath, P.M., et al., Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. The Lancet, 2018. 391(10123): p. 850-859.

12. VITATOPS Trial Study Group, B vitamins in patients with recent transient ischaemic attack or stroke in the VITamins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol, 2010. 9(9): p. 855-65.

13. Heels-Ansdell, D., et al. Methods Center Adjudication Costs For 5 Morbidity Outcomes In A Thromboprophylaxis Trial. 2011. American Thoracic Society.

14. Godolphin, P.J., et al., Central adjudication of serious adverse events did not affect trial’s safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. PLOS ONE, 2018. 13(11): p. e0208142.

15. Godolphin, P.J., et al., Outcome assessment by central adjudicators in randomised stroke trials: simulation of differential and non-differential misclassification. European Stroke Journal, 2020. https://doi.org/10.1177/2396987320910047.

16. Kahan, B.C., B. Feagan, and V. Jairath, A comparison of approaches for adjudicating outcomes in clinical trials. Trials, 2017. 18(1): p. 266.
Tables:

Table 1: Characteristics of included trials

| Year of main trial publication | Included (n=9) |
|-------------------------------|---------------|
| 1990-2000                     | 2 (22%)       |
| 2001-2005                     | 1 (11%)       |
| 2006-2010                     | 2 (22%)       |
| 2011-2015                     | 2 (22%)       |
| 2016-2018                     | 2 (22%)       |

| Study design                  |               |
|-------------------------------|---------------|
| Parallel                      | 8 (89%)       |
| Factorial                     | 1 (11%)       |

| Type of trial                 |               |
|-------------------------------|---------------|
| Primary prevention            | 1 (11%)       |
| Secondary prevention          | 6 (67%)       |
| Acute stroke                  | 2 (22%)       |

| Participants randomised       |               |
|-------------------------------|---------------|
| Mean (SD)                     | 2826 (2744)   |
| Median [25th, 75th centile]   | 2739 [449, 3096] |
| Min, Max                      | 129, 8164     |

| No. of sites                  |               |
|-------------------------------|---------------|
| Mean (SD)                     | 86 (49)       |
| Median [25th, 75th centile]   | 79 [50, 123]  |
| Min, Max                      | 17, 172       |

| Intervention                  |               |
|-------------------------------|---------------|
| Drug                          | 6 (67%)       |
| Surgery/procedure             | 2 (22%)       |
| Other                         | 1 (11%)       |

| Comparator                    |               |
|-------------------------------|---------------|
| Placebo                       | 2 (22%)       |
| Standard care                 | 6 (67%)       |
| Surgery/procedure             | 1 (11%)       |

| Primary outcome               |               |
|-------------------------------|---------------|
| Stroke                        | 6 (67%)       |
| Composite including stroke    | 3 (33%)       |

| Blinding status of site       |               |
|investigators                  |               |
|-------------------------------|---------------|
| Blind to treatment allocation | 4 (44%)       |
| Not blind to treatment        | 5 (56%)       |
Table 2: Time taken for adjudication and dealing with disagreements

| Trial name | Events adjudicated | Number of adjudications per event | Time per adjudication (minutes) | Total time for adjudication (hours) | Adjudicator hourly salary | Cost of adjudication* |
|------------|--------------------|----------------------------------|---------------------------------|-------------------------------------|---------------------------|-----------------------|
| CABACS     | 34                 | Once                             | 10                              | 5.7                                 | £67.62                    | £723.18               |
| ESPRIT     | 440                | Three                            | 5                               | 110                                 | £62.40                    | £20064                |
| FASTEST    | 24                 | Once                             | 45                              | 18                                  | £70.16                    | £1502.88              |
| HAEST      | 93                 | Once                             | 15                              | 23.25                               | £47.62                    | £2037.17              |
| J-STARS    | 239                | Once                             | 30                              | 119.5                               | £47.62                    | £8060.59              |
| NASCET     | 436                | Twice                            | 120                             | 1744                                | £47.62                    | £91769.28             |
| PROGRESS   | 992                | Once                             | 15                              | 248                                 | £48.22                    | £21878.56             |
| TARDIS     | 1656               | Twice                            | 10                              | 552                                 | £49.40                    | £60388.80             |
| VITATOPS   | 1260               | Once                             | 20                              | 420                                 | £96.40                    | £53088                |

*Calculated as: Cost of adjudication = (Total time for adjudication)*(Adjudicator hourly salary) + [(Events adjudicated)*Number of adjudication per event)*£10]
Table 3: Cost of adjudication per corrected event by included trial

| Trial name | Coordinating centre cost* | Adjudication cost | Disagreement cost | Total cost | Number of events corrected after adjudication | Cost per corrected event |
|------------|---------------------------|-------------------|-------------------|------------|-----------------------------------------------|--------------------------|
| CABACS     | £0                        | £723.18           | £0                | £2733.18   | 0                                             | NA                       |
| ESPRIT     | £18250                    | £20064            | £114.40           | £38428.40  | 51                                            | £753.50                  |
| FASTEST    | £1610                     | £1502.88          | £631.44           | £3744.32   | 0                                             | NA                       |
| HAEST      | £4370                     | £2037.17          | £0                | £6407.17   | 2                                             | £3203.58                 |
| J-STAR     | £10210                    | £8080.59          | £2381             | £20671.59  | 10                                            | £2067.16                 |
| NASCET     | £18090                    | £91769.28         | £1285.74          | £111145.02 | 27                                            | £4116.48                 |
| PROGRESS   | £40330                    | £21878.56         | £0                | £62208.56  | 98                                            | £634.78                  |
| TARDIS     | £66890                    | £60388.80         | £8348.60          | £135627.40 | 34                                            | £3989.04                 |
| VITATOPS   | £51050                    | £53088            | £1253.20          | £105391.20 | 81                                            | £1301.13                 |

|               | Mean (SD)†               |                   |                   |           |                                               |                          |
|---------------|--------------------------|-------------------|-------------------|-----------|-----------------------------------------------|--------------------------|
|               | £2295.10                 | (1482.42)         |                   |           |                                               |                          |
| Median†       | £2067.16                 |                   |                   |           |                                               |                          |
| Min†          | £634.78                  |                   |                   |           |                                               |                          |
| Max†          | £4116.48                 |                   |                   |           |                                               |                          |

*Coordinating centre cost includes £650 set-up cost and £40 cost per event
†Summary statistics do not include CABACS or FASTEST